MarketCap
Facebook
X
TelegramQuarterly report 2026-Q1
added 05-11-2026
Stryker Corporation Long-Term Debt 2011-2026 | SYK
Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.
Main characteristics:- Term exceeds 12 months
- Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
- Repaid through regular payments (interest and/or principal) over several years
- Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital. - Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks. - Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.
A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.
If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.
It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.
Examples of long-term debt:- Mortgage loans for property purchases
- Corporate bonds issued by a company to raise capital
- Project financing — long-term loans for building or expanding production facilities
- Leasing obligations for equipment or transport
Annual Long-Term Debt Stryker Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.9 B | 12.2 B | 10.9 B | 11.9 B | 12.5 B | 13.2 B | 10.2 B | 8.49 B | 6.59 B | 6.69 B | 3.25 B | 3.25 B | 2.74 B | 1.75 B | 1.75 B | 996 M | 18 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.9 B | 18 M | 7.13 B |
Quarterly Long-Term Debt Stryker Corporation
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.2 B | 14.8 B | 14.8 B | 14.4 B | 13.3 B | 10.1 B | 10.8 B | 10.4 B | 11.1 B | 11.9 B | 11.9 B | 12.8 B | - | 13.9 B | 12.5 B | 12.6 B | 12.7 B | 13.1 B | 13.2 B | 13.2 B | 13.2 B | 13.2 B | 10.2 B | 10.2 B | 10.2 B | 10.2 B | 8.49 B | 8.49 B | 8.49 B | 8.49 B | 6.59 B | 6.59 B | 6.59 B | 6.59 B | 6.69 B | 6.69 B | 6.69 B | 6.69 B | 3.23 B | 3.23 B | 3.23 B | 3.23 B | 3.25 B | 3.25 B | 3.25 B | 3.25 B | 2.74 B | 2.74 B | 2.74 B | 2.74 B | 1.75 B | 1.75 B | 1.75 B | 1.75 B | 1.75 B | 1.75 B | 1.75 B | 1.75 B | 996 M | 996 M | 996 M | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.8 B | 996 M | 7.5 B |
Long-Term Debt of other stocks in the Medical devices industry
| Issuer | Long-Term Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
GenMark Diagnostics, Inc.
GNMK
|
71.3 M | - | - | $ 1.77 B |  USA |
 |
Avinger
AVGR
|
1.1 M | - | -20.74 % | $ 369 K | USA |
 |
Axonics Modulation Technologies
AXNX
|
25.8 M | - | - | $ 3.31 B | USA |
 |
Allied Healthcare Products
AHPI
|
2.93 K | - | 3.58 % | $ 2.21 M | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
430 K | - | -5.86 % | $ 30.6 M | USA |
 |
ClearPoint Neuro
CLPT
|
49.1 M | $ 11.16 | -0.09 % | $ 316 M | USA |
 |
Apollo Endosurgery
APEN
|
34 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
501 M | $ 8.27 | 0.55 % | $ 1.24 B | USA |
 |
Aziyo Biologics
AZYO
|
3.59 M | - | 1.37 % | $ 20.5 M | USA |
 |
EDAP TMS S.A.
EDAP
|
2.16 M | $ 4.33 | 0.23 % | $ 162 M |  France |
 |
BioSig Technologies
BSGM
|
103 K | - | 37.08 % | $ 85.7 M | USA |
 |
BIOLASE
BIOL
|
11.8 M | - | -13.19 % | $ 166 K | USA |
 |
Conformis
CFMS
|
20.6 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
1.33 M | - | 0.15 % | $ 844 M | USA |
 |
LENSAR
LNSR
|
1.99 M | $ 5.86 | 1.03 % | $ 70.1 M | USA |
 |
Helius Medical Technologies
HSDT
|
12 K | $ 2.31 | 6.94 % | $ 50.9 M | USA |
 |
CryoLife, Inc.
CRY
|
290 M | - | -4.14 % | $ 702 M | USA |
 |
Cytosorbents Corporation
CTSO
|
16.7 M | $ 0.47 | -0.53 % | $ 29.2 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
99.8 M | $ 18.4 | 0.93 % | $ 432 M | USA |
 |
LivaNova PLC
LIVN
|
345 M | $ 73.67 | 1.03 % | $ 4.02 B |  Britain |
 |
MiMedx Group
MDXG
|
16.5 M | $ 3.77 | 3.43 % | $ 557 M | USA |
 |
Delcath Systems
DCTH
|
835 K | $ 11.2 | 3.23 % | $ 401 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
154 K | - | 0.03 % | $ 1.58 B |  Israel |
 |
Misonix, Inc.
MSON
|
38.6 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
273 K | - | - | $ 111 M |  Canada |
 |
IRIDEX Corporation
IRIX
|
98 K | $ 1.0 | -4.29 % | $ 16.9 M | USA |
 |
Dynatronics Corporation
DYNT
|
1.11 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
11.9 M | - | - | $ 10.2 M | USA |
 |
Pulmonx Corporation
LUNG
|
37 M | $ 1.54 | 14.55 % | $ 62.7 M | USA |
 |
Electromed
ELMD
|
1.1 M | $ 37.58 | -2.06 % | $ 318 M | USA |
 |
Myomo
MYO
|
11.2 M | $ 0.9 | 3.7 % | $ 37.7 M | USA |
 |
Butterfly Network
BFLY
|
17.7 M | $ 4.42 | 7.8 % | $ 1.09 B | USA |
 |
Intersect ENT, Inc.
XENT
|
63.6 M | - | - | $ 955 M | USA |
 |
Second Sight Medical Products
EYES
|
17.1 M | - | -0.97 % | $ 54.4 M | USA |
 |
Orthofix Medical
OFIX
|
157 M | $ 12.16 | 0.58 % | $ 482 M |  Curacao |
 |
GBS
GBS
|
1.65 M | - | -0.57 % | $ 7.12 M | USA |
 |
Sintx Technologies
SINT
|
2.84 M | $ 2.19 | -0.45 % | $ 6.07 M | USA |
 |
Profound Medical Corp.
PROF
|
4.5 M | $ 6.95 | 3.19 % | $ 210 M | Canada |
 |
Globus Medical
GMED
|
436 K | $ 83.98 | 5.06 % | $ 11.4 B | USA |
 |
Insulet Corporation
PODD
|
931 M | $ 157.2 | 1.68 % | $ 11.1 B | USA |
 |
CONMED Corporation
CNMD
|
834 M | $ 36.7 | 1.44 % | $ 1.14 B | USA |
 |
Inspire Medical Systems
INSP
|
30 M | $ 44.19 | 3.87 % | $ 1.3 B | USA |
 |
TransMedics Group
TMDX
|
453 M | $ 68.79 | 4.01 % | $ 2.34 B | USA |
 |
Integer Holdings Corporation
ITGR
|
1.19 B | $ 91.17 | 0.81 % | $ 3.17 B | USA |
 |
Invacare Corporation
IVC
|
354 M | - | - | $ 24.7 M | USA |
 |
Edwards Lifesciences Corporation
EW
|
598 M | $ 82.96 | 0.97 % | $ 48.5 B | USA |